UPL: HSBC maintains a Buy on UPL with a Target Price of ₹880 (cut), citing a strong 4QFY26 beat led by Global Crop Protection and Advanta businesses with growth across all regions except India, while noting that UPL exceeded all FY26 guidance parameters and its strengthened balance sheet leaves it well-positioned to navigate ongoing uncertainties.

 13 May 2026 08:39 AM

UPL: HSBC maintains a Buy on UPL with a Target Price of ₹880 (cut), citing a strong 4QFY26 beat led by Global Crop Protection and Advanta businesses with growth across all regions except India, while noting that UPL exceeded all FY26 guidance parameters and its strengthened balance sheet leaves it well-positioned to navigate ongoing uncertainties.

UPL: Guidance - For Q1 FY27, UPL guides for 10% to 14% revenue growth and 14% to 18% EBITDA growth, noting Q1 is typically a slower quarter with lower EBITDA margins due to seasonality. - Concall Update

 12 May 2026 08:57 AM

UPL: Guidance - For Q1 FY27, UPL guides for 10% to 14% revenue growth and 14% to 18% EBITDA growth, noting Q1 is typically a slower quarter with lower EBITDA margins due to seasonality. - Concall Update

UPL: Guidance - Q1 FY27 revenue growth is expected to be driven by volume growth in India SAS, Advanta, and SUPERFORM, with UPL Corp. being largely flat, alongside positive price impact and a 7% to 9% positive FX impact. - Concall Update

 12 May 2026 08:57 AM

UPL: Guidance - Q1 FY27 revenue growth is expected to be driven by volume growth in India SAS, Advanta, and SUPERFORM, with UPL Corp. being largely flat, alongside positive price impact and a 7% to 9% positive FX impact. - Concall Update

UPL: Guidance - For FY27, CapEx is projected to be between $300 million to $350 million, an increase from FY26's $261 million, to enhance margins and build additional EBITDA, particularly in specialty chemicals and backward integration. - Concall Update

 12 May 2026 08:57 AM

UPL: Guidance - For FY27, CapEx is projected to be between $300 million to $350 million, an increase from FY26's $261 million, to enhance margins and build additional EBITDA, particularly in specialty chemicals and backward integration. - Concall Update

UPL: Guidance - The company aims for a comfortable working capital cycle time of around 65 days, compared to the 53 to 57 days achieved in the last two years, and a medium-term net debt to EBITDA ratio of 1.2 to 1.5 times. - Concall Update

 12 May 2026 08:58 AM

UPL: Guidance - The company aims for a comfortable working capital cycle time of around 65 days, compared to the 53 to 57 days achieved in the last two years, and a medium-term net debt to EBITDA ratio of 1.2 to 1.5 times. - Concall Update

UPL: Guidance - The effective tax rate for FY27 is guided to be around 20% to 22%, with the NPP segment targeting a CAGR of approximately 12% between FY26 and FY31, and $700 million in revenue for FY27, aiming for $1 billion by FY31. - Concall Update

 12 May 2026 08:58 AM

UPL: Guidance - The effective tax rate for FY27 is guided to be around 20% to 22%, with the NPP segment targeting a CAGR of approximately 12% between FY26 and FY31, and $700 million in revenue for FY27, aiming for $1 billion by FY31. - Concall Update

UPL: Jefferies maintains a Buy on UPL with a Target Price of ₹810, noting that while Q4 OPM and RPAT missed estimates despite a sales beat, FY26 saw strong deleveraging with gross debt reduced by $850mn to $2.3bn and net debt/EBITDA improving to below 1.6x, alongside stable working capital, with management guiding 10–14% sales and 14–18% EBITDA growth in Jun26-Q and valuation at 15x FY27E P/E in line with its 5-year average after a 17% YTD decline.

 12 May 2026 08:40 AM

UPL: Jefferies maintains a Buy on UPL with a Target Price of ₹810, noting that while Q4 OPM and RPAT missed estimates despite a sales beat, FY26 saw strong deleveraging with gross debt reduced by $850mn to $2.3bn and net debt/EBITDA improving to below 1.6x, alongside stable working capital, with management guiding 10–14% sales and 14–18% EBITDA growth in Jun26-Q and valuation at 15x FY27E P/E in line with its 5-year average after a 17% YTD decline.

UPL: Kotak Institutional Equities maintains a Reduce on UPL with a Target Price of ₹650, as strong 18% YoY revenue growth in 4QFY26 aided by FX gains was offset by a voluntary provision and higher tax rate weighing on earnings, while uncertain outlook with limited guidance visibility, ongoing reorganization plans, and a sizeable US$87mn Sinova investment at elevated valuations remain key concerns.

 12 May 2026 08:40 AM

UPL: Kotak Institutional Equities maintains a Reduce on UPL with a Target Price of ₹650, as strong 18% YoY revenue growth in 4QFY26 aided by FX gains was offset by a voluntary provision and higher tax rate weighing on earnings, while uncertain outlook with limited guidance visibility, ongoing reorganization plans, and a sizeable US$87mn Sinova investment at elevated valuations remain key concerns.

UPL: Company Reports War's Effect On Manufacturing Activities

 11 May 2026 02:33 PM

UPL: Company Reports War's Effect On Manufacturing Activities

UPL: Sets Q1 FY27 Revenue Growth Target Of 10-14% And EBITDA Growth Target Of 14-18%.

 11 May 2026 01:32 PM

UPL: Sets Q1 FY27 Revenue Growth Target Of 10-14% And EBITDA Growth Target Of 14-18%.

UPL: CFO Reports $500M Debt Repaid In March To Improve Balance Sheet And Refinance Upcoming Obligations For Better Liquidity.

 11 May 2026 01:27 PM

UPL: CFO Reports $500M Debt Repaid In March To Improve Balance Sheet And Refinance Upcoming Obligations For Better Liquidity.

UPL: Q4 CONS NET PROFIT 10.6B RUPEES VS 9B (YOY); EST 13B

 11 May 2026 01:19 PM

UPL: Q4 CONS NET PROFIT 10.6B RUPEES VS 9B (YOY); EST 13B

UPL: Q4 REVENUE 183B RUPEES VS 156B (YOY)

 11 May 2026 01:19 PM

UPL: Q4 REVENUE 183B RUPEES VS 156B (YOY)

UPL: Q4 EBITDA 35.6B RUPEES VS 31.9B (YOY) || Q4 EBITDA MARGIN 19.41% VS 20.5% (YOY)

 11 May 2026 01:20 PM

UPL: Q4 EBITDA 35.6B RUPEES VS 31.9B (YOY) || Q4 EBITDA MARGIN 19.41% VS 20.5% (YOY)

UPL: FY26 EBITDA MARGIN AT 17.9% VS GUIDANCE 12- 16% FOR FULL YEAR

 11 May 2026 01:21 PM

UPL: FY26 EBITDA MARGIN AT 17.9% VS GUIDANCE 12- 16% FOR FULL YEAR

UPL: FY26 REVENUE GROWTH OF 10% VS GUIDANCE OF 4 - 8% FOR FULL YEAR

 11 May 2026 01:22 PM

UPL: FY26 REVENUE GROWTH OF 10% VS GUIDANCE OF 4 - 8% FOR FULL YEAR

UPL: Brazilian Arm Will Invest About $86.7 Million More In Associate Sinova Lnovacoes Agricola

 25 Apr 2026 04:04 PM

UPL: Brazilian Arm Will Invest About $86.7 Million More In Associate Sinova Lnovacoes Agricola

UPL: Nuvama on UPL Downgrade to Hold, Target Price Rs 816

 23 Feb 2026 09:12 AM

UPL: Nuvama on UPL Downgrade to Hold, Target Price Rs 816

UPL: States FY26 Targets Are Progressing Well

 02 Feb 2026 03:01 PM

UPL: States FY26 Targets Are Progressing Well

UPL: Co's Net Debt Decreases By ₹2,500 Crore Compared To Last Year.

 02 Feb 2026 03:01 PM

UPL: Co's Net Debt Decreases By ₹2,500 Crore Compared To Last Year.